Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people ...
Introduction Lupus nephritis (LN) exhibits substantial clinical and pathological heterogeneity. We aimed to define proteomics-based molecular subtypes of LN and identify candidate biomarkers for ...
Operator: Good morning, everyone, and welcome to the Annexon Business Update Call. [Operator Instructions] As a reminder, ...
Immune checkpoint inhibitors have revolutionized cancer treatment, yet many colorectal tumors remain resistant. Even among patients who initially respond, more than half eventually develop resistance, ...
Antigen-specific humoral responses are critical for long-term protection against infectious diseases, yet the mechanisms that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results